Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
This article is no longer freely available.
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
November 29, 2021 (Issue: 1638)
The FDA has licensed two new pneumococcal
conjugate vaccines (PCVs) for prevention of invasive
pneumococcal disease in adults: Prevnar 20 (PCV20;
Pfizer), which contains antigens from 20 serotypes of
pneumococcus, and Vaxneuvance (PCV15;...more
- Adult immunization. Med Lett Drugs Ther 2018; 60:73.
- S Tomczyk et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822.
- ME Pichichero. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother 2013; 9:2505.
- M Kobayashi. Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options. ACIP Meeting. October 20, 2021. Available at: https://bit. ly/2YhkaOi. Accessed November 10, 2021.
- MJM Bonten et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114.
- D Hurley et al. Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age. Clin Infect Dis 2021; 73:e1489.
- HL Platt et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine 2021 September 7 (epub).
- JY Song et al. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: a randomized phase III trial (PNEU-PATH). Vaccine 2021; 39:6422.
- American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 741: maternal immunization. Obstet Gynecol 2018; 131:e214.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
Article code: 1638c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
